Nivolumab plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

Scott N. Gettinger, Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Leighl, Suresh S. Ramalingam, Susan S. Tavernier, Hui Yu, Joseph M. Unger, Katherine Minichiello, Louise Highleyman, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara, Roy S. Herbst

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab plus Ipilimumab vs Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences